scPharmaceuticals, Inc.
http://www.scpharmaceuticals.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From scPharmaceuticals, Inc.
Finance Watch: Emalex Raises $250m To Fund Phase III Tourette’s Trial
Private Company Edition: The Paragon Biosciences-founded Emalex previously raised $35m when ecopipam was in Phase II. Also, Catalio Capital launches a “special situations” fund, Zenas raises $118m to develop a pipeline of autoimmune disease treatments and Lusaris emerges with $60m.
Finance Watch: Prime Medicine Launches Second-Largest IPO In Second Half Of 2022
Public Company Edition: Prime Medicine raised $175m, making its offering the sixth-largest out of 19 biopharma IPOs in the US this year. Also, Oculis and AUM opted to go public via SPAC mergers, Insmed raised $775m from multiple financings and Dice capitalized on positive data with a $300m offering.
Keeping Track: Furoscix, SPN-830 Show Difficulties Of Drug-Device Combinations
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
October Outlook For US FDA Approvals: Goal Dates Are Sparse, But Backlog Looms
Upcoming user fee goal dates include AstraZeneca’s tremelimumab, Amicus’ AT-GAA, and drug delivery technology-driven NDAs from Supernus/US Worldmeds and scPharmaceuticals
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice